Q-omics provides the consensus-scored MIR3936HG profile across patient tissues and cancer cell-line models. MIR3936HG expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR3936HG is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, MIR3936HG RNA expression shows 19,761 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where MIR3936HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3936HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3936HG survival associations across molecular data types. MIR3936HG RNA expression shows survival associations in the most cancer types (29). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3936HG RNA expression–survival associations across cancer types. High MIR3936HG expression shows unfavorable associations in CESC and BLCA, but favorable associations in ACC, MESO, BRCA and UCS. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR3936HG RNA expression.
This table summarizes MIR3936HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3936HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3936HG shows lower tumor expression in COAD, KICH, THCA, LUSC and BRCA and higher tumor expression in LIHC. The COAD box plot shows higher MIR3936HG RNA expression in normal versus tumor tissue (log2 FC = −0.639, t-test p < 0.001).
This table shows molecular features associated with MIR3936HG in patient tissues and cancer cell lines. In patient samples, MIR3936HG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
